Recap: Myriad Genetics Q4 Earnings

Shares of Myriad Genetics MYGN moved higher by 1.64% in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share fell 175.61% year over year to ($0.31), which beat the estimate of ($0.47).

Revenue of $93,200,000 declined by 56.73% year over year, which missed the estimate of $93,850,000.

Outlook

Myriad Genetics hasn't issued any earnings guidance for the time being.

Myriad Genetics hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Aug 13, 2020

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/6w3d9td9

Recent Stock Performance

52-week high: $47.10

Company's 52-week low was at $9.24

Price action over last quarter: down 5.97%

Company Profile

Myriad Genetics is a molecular diagnostics company, which provides testing services designed to assess an individual's risk of developing a disease. The firm produces myRisk, a 28-gene panel with the capability to identify the elevated risk of developing 8 types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Vectra DA, which predicts disease progression in rheumatoid arthritis to optimize drug treatment; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.